Hospital resource utilization and costs of inappropriate treatment of candidemia

Pharmacotherapy

Volumn 30, Issue 4, 2010, Pages 361-368

  Arnold, Heather M ^a   Micek, Scott T ^a   Shorr, Andrew F ^b   Zilberberg, Marya D ^c,d   Labelle, Andrew J ^e   Kothari, Smita ^f   Kollef, Marin H ^e  

^a BARNES JEWISH HOSPITAL   (United States)

^b GEORGETOWN UNIVERSITY   (United States)

^c EviMed Research Group LLC   (United States)

^d UNIVERSITY OF MASSACHUSETTS   (United States)

^e WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f Astellas Pharma US Inc   (United States)

Author keywords

Candidemia; Echinocandin; Fluconazole; Resource utilization

Indexed keywords

AMPHOTERICIN B; ANTIFUNGAL AGENT; CASPOFUNGIN; FLUCONAZOLE; VORICONAZOLE;

ADULT; ARTICLE; BLOODSTREAM INFECTION; CANDIDA ALBICANS; CANDIDA GLABRATA; CANDIDA KRUSEI; CANDIDA PARAPSILOSIS; CANDIDA TROPICALIS; CANDIDEMIA; COHORT ANALYSIS; FEMALE; FUNGUS CULTURE; FUNGUS ISOLATION; HEALTH CARE COST; HOSPITAL; HOSPITAL ADMISSION; HOSPITAL UTILIZATION; HOSPITALIZATION; HUMAN; IN VITRO STUDY; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; NONHUMAN; RETROSPECTIVE STUDY; RISK FACTOR; TREATMENT OUTCOME;

ADULT; ANTIFUNGAL AGENTS; CANDIDA; CANDIDIASIS; CATHETERIZATION, CENTRAL VENOUS; COHORT STUDIES; COSTS AND COST ANALYSIS; HOSPITAL COSTS; HOSPITALIZATION; HUMANS; RETROSPECTIVE STUDIES; RISK FACTORS;

EID: 77950414961     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.30.4.361     Document Type: Article

References (20)

1. Zilberberg MD, Shorr AF, Kollef MH. Secular trends in candidemia-related hospitalization in the United States, 2000-2005. Infect Control Hosp Epidemiol 2008;29:978-980
2. Wey SB, Mori M, Pfaller MA, Woolson RF, Wenzel RP. Hospital-acquired candidemia: the attributable mortality and excess length of stay. Arch Intern Med 1988;148:2642-2645
3. Zaoutis TE, Argon J, Chu J, Berlin JA, Walsh TJ, Feudtner C. The epidemiology and attributable outcomes of candidemia in adults and children hospitalized in the United States: a propensity analysis. Clin Infect Dis 2005;41:1232-1239
4. Pfaller MA, Diekema DJ. Epidemiology of invasive candidiasis: a persistent public health problem. Clin Microbiol Rev 2007;20:133-163
5. Trick WE, Fridkin SK, Edwards JR, Hajjeh RA, Gaynes RP, for the National Nosocomial Infections Surveillance System Hospitals. Secular trend of hospital-acquired candidemia among intensive care unit patients in the United States during 1989-1999. Clin Infect Dis 2002;35:622-630
6. Pfaller MA, Diekema DJ, Gibbs DL, et al. Results from the ARTEMIS DISK global antifungal surveillance study, 1997 to 2005: an 8.5-year analysis of susceptibilities of Candida species and other yeast species to fluconazole and voriconazole determined by CLSI standardized disk diffusion testing. J Clin Microbiol 2007;45:1735-1745
7. Morrell M, Fraser VJ, Kollef MH. Delaying the empiric treatment of Candida bloodstream infection until obtaining positive blood culture results: a potential risk factor for hospital mortality. Antimicrob Agents Chemother 2005;49:3640-3645
8. Garey KW, Rege M, Pai MP, et al. Time to initiation of fluconazole therapy impacts mortality in patients with candidemia: a multicenter study. Clin Infect Dis 2006;43:25-31.
9. Labelle AJ, Micek ST, Roubinian N, Kollef MH. Treatment-related risk factors for hospital mortality in Candida bloodstream infections. Crit Care Med 2008;36:2967-2972
10. Tumbarello M, Posteraro B, Trecarichi EM, et al. Biofilm production by Candida species and inadequate antifungal therapy as predictors of mortality in patients with candidemia. J Clin Microbiol 2007;45:1843-1850
11. Shorr AF, Micek ST, Kollef MH. Inappropriate therapy for methicillin-resistant Staphylococcus aureus: resource utilization and cost implications. Crit Care Med 2008;36:2335-2340
12. Shorr AF, Micek ST, Jackson WL, Kollef MH. Economic implications of an evidence-based sepsis protocol: can we improve outcomes and lower costs? Crit Care Med 2007;35: 1257-1262
13. Morgan J, Meltzer MI, Plikaytis BD, et al. Excess mortality, hospital stay, and cost due to candidemia: a case-control study using data from population-based candidemia surveillance. Infect Control Hosp Epidemiol 2005;26:540-547
14. Garey KW, Turpon RS, Bearden DT, et al. Economic analysis of inadequate fluconazole therapy in non-neutropenic patients with candidemia: a multi-institutional study. Int J Antimicrob Agents 2007;29:557-562
15. Sofair AN, Lyon GM, Huie-White S, et al. Epidemiology of community-onset candidemia in Connecticut and Maryland. Clin Infect Dis 2006;43:32-39
16. Shorr AF, Lazarus DR, Sherner JH, et al. Do clinical features allow for accurate prediction of fungal pathogenesis in bloodstream infections? Potential implications of the increasing prevalence of non-albicans candidemia. Crit Care Med 2007;35:1077-1083
17. Chow JK, Golon Y, Ruthazer R, et al. Risk factors for albicans and non-albicans candidemia in the intensive care unit. Crit Care Med 2008;36:1993-1998
18. Playford E, Marriot D, Nguyen Q, et al. Candidemia in non-neutropenic critically ill patients: risk factors for non-albicans Candida spp. Crit Care Med 2008;36:2034-2039
19. Sobel JD. Changing epidemiology of invasive candidiasis in intensive care units: much ado about nothing? Crit Care Med 2008;36:2188-2189
20. Pappas PG, Kauffman CA, Andes D, et al. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis 2009;48:503-535